SCHEMBL8440690

SCHEMBL8440690

CCOC(=O)N1CCN(Cc2cccc(N=O)c2)CC1

nearest known ligand 0.62

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.56
KDM4E B2RXH2 6/20 0.56
POLB P06746 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TDP1 Q9NUW8 2/20 0.51
ALOX15 P16050 2/20 0.51
HTT P42858 2/20 0.50
LMNA P02545 2/20 0.50
L3MBTL1 Q9Y468 3/20 0.48
MAPT P10636 2/20 0.47
KMT2A Q03164 2/20 0.47
MPI P34949 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2652152 0.82 ALDH1A1 (0.59) ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10
SCHEMBL7475308 0.81 ALDH1A1 (0.70) ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10
SCHEMBL2662019 0.78 ALDH1A1 (0.67) ALDH1A1KDM4EPOLBSMN1; SMN2TDP1
SCHEMBL9819725 0.76 ALDH1A1 (0.64) ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10
SCHEMBL19847120 0.76 NOS1 (0.42) ALDH1A1KDM4ESMN1; SMN2HSD17B10HTT
SCHEMBL9819832 0.76 MEN1 (0.68) ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10
SCHEMBL11093397 0.74 DRD2 (0.70) ALDH1A1KDM4EPOLBSMN1; SMN2TDP1
SCHEMBL8440683 0.73 SIGMAR1 (0.46) ALDH1A1KDM4ESMN1; SMN2HSD17B10TDP1
SCHEMBL4466600 0.73 ALDH1A1 (0.59) ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10
SCHEMBL27481117 0.73 FAAH (0.50) ALDH1A1KDM4EPOLBHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040097570-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds NEUROSEARCH A/S 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097570-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds GABRA1, GABRA2, GABRA4 ALDH1A1 977/4885KDM4E 851/4885POLB 4499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.